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y-Hydroxybutyrate (GHB) is a putative neurotransmitter in brain. We have already demonstrated that it 
is transformed into y-aminobutyrate (GABA) by rat brain slices incubated under physiological conditions. 
This conversion occurs via a GABA-transaminase reaction. Therefore, succinic semialdehyde, the oxidative 
derivative of GHB, appears to be the primary catabolite of GHB degradation. Apparently, the kinetic cha- 
racteristics ‘and pH optimum of GHB dehydrogenase (high K, aldehyde reductase) in vitro do not favor 
a role for this enzyme in endogenous brain GHB oxidation. However, in the presence of glucuronate, glu- 
tamate, NADP and pyridoxal phosphate, pure GHB dehydrogenase, coupled to purified GABA-transamin- 
ase does produce GABA from GHB at an optimum pH close to the physiological value and with a low 
K, for GHB. 
1, INTRODUCTION 
In brain, GHB fulfills the main criteria generally 
accepted for defining a neurotransmitter [l). Its 
biosynthesis [2,3], transport [4], binding [5], 
release [6] and turnover rate [7] suggest hat GHB 
plays an important role at the synaptic level. 
Recently we have described the catabolic pathway 
of this compound [8]. t3H]GHB incubated in vitro 
under physiological conditions with rat brain slices 
produces [3H]y-aminobutyrate (t3H]GABA). This 
transformation does not occur via succinate 
foliowed by the Krebs cycle, and it is strongly 
decreased by all the GABA-T inhibitors tested. 
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Therefore, it seems likely that the first step of 
GHB catabolism is its oxidation to SSA via a GHB 
dehydrogenase, followed by the transamination of 
SSA to GABA via GABA-T. 
An NADP-linked enzyme, able to interconvert 
GHB and SSA has been partially purified from 
hamster liver and brain 191. This enzyme, which 
has an A& of 38000 by SDS-PAGE, can reduce 
SSA with NADPH as cofactor at a pH optimum of 
6.7. This reaction is inhibited by barbiturates, 
sodium valproate, phenylhydantoins and ethosuxi- 
mide. D-Glucuronate appears to be a good sub- 
strate for this enzyme. Therefore, it seems that the 
GHB dehydrogenase purified by Kaufman et al. 
[9] is the high K,, aldehyde reductase isolated and 
purified by several authors (review [lo]). This 
enzyme, designated as ALRl (EC 1.1.1.2 [ll]) or 
succinic semialdehyde reductase (SSR1) [2] can 
oxidize GHB to SSA. However, in view of the 
kinetic characteristics of the GHB dehydrogena- 
tion reaction, its role in the catabolism of the very 
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low endogenous concentration of GHB in brain 
may be questionable. We demonstrate in this work 
that purified GHB dehydrogenase (ALRi or SSRi) 
and purified GABA-T, both from rat brain, added 
together are able to rapidly transform very small 
amounts of GHB into GABA. 
2. MATERIALS AND METHODS 
[2,3-3H]GHB potassium salt (spec. radioact. 
40 Ci/mmol) was obtained from the CEA 
(France). Radiochemical purity was checked by 
thin layer chromatography in 3 different solvent 
systems as described [5]. 
For determination of GHB dehydrogenase ac- 
tivity, the initial rate of NADP reduction at 37°C 
was measured in phosphate buffer (300 mM, pH 
8.0) containing 5 mM Bmercaptoethanol, 5 mM 
AET and suitable amounts of GHB and NADP 
(usually 10 mM and 50 ,uM, respectively). The in- 
crease in NADPH fluorescence was measured at 
excitation 355 nm and emission 470 nm. In some 
cases, measurements of SSA production were car- 
ried out with cyclohexane 1,fdione according to 
Beeler and Churchich 1121. 
The activity of the coupled enzyme reaction 
(GHB dehydrogenase plus GABA-T) was 
measured as follows: radioactive GHB ({2,3-3H]- 
GHB, 40 Ci/mmol) at a specific activity of 700 
mCi/mmol was incubated in 500 ,~l of 300 mM 
phosphate buffer (pH 8.0) containing 5 mM p- 
mercaptoethanol, 5 mM AET, 0.5 mM pyridoxal 
phosphate, 0.5 mM glutamate, 2 mM glucuronate, 
50pM NADP and a suitable amount of purified 
GHB dehydrogenase (8 units) and purified GABA- 
T (10.3 units) (1 unit = 1 nmol SSA formed/min). 
These two levels of activities were chosen due to 
the similar specific activities of the two enzymes in 
homogenates of rat brain [ 13,14]. After incubation 
for 5 min at 37”C, the’ reaction was stopped by 
adding SO/;11 of 100% trichloroacetic acid. The 
[3H]GABA formed was separated from [3H]GHB 
by ion-exchange chromatography using Dowex 
50 W X 8 (H+ form) resin packed into a Pasteur 
pipette (bed volume 3 x 0.5 cm). The column was 
rinsed 4 times with 1 ml distilled HzO, and the 
amino acid fraction was eluted from the column 
with 1 M ammonium hydroxide and mixed with 
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5 ml Instagel (Packard Instruments) in a scintilla- 
tion vial. Radioactivity was determined using a 
Beckman ,J? counter at about 40% efficiency. Elu- 
tion profiles of standards solution of [3H]GHB or 
[3H]GABA indicate clear cut separation. 
2.2. Enzyme extraction and purification 
2.2.1. High &, ALRl 
High Km ALRt which is identical to non-specific 
SSRl and glucuronate reductase [ll] has been 
purified as described [2]. This enzyme is named 
GHB dehydrogenase in this work. 
22.2. GABA-T 
GABA-T from rat brain was partially purified 
(about 300-fold with regard to the initial 
homogenate). An acetone powder, prepared as 
described by Roberts and Frankel [15], was used as 
a source of enzyme. An acetone powder from 15 
rat brains was homogenized in 100 ml of 2 mM 
phosphate buffer (pH 7.2) containing 5 mM P- 
mercaptoethanol, 5 mM AET and 0.5 mM 
pyridoxal phosphate. After rapid centrifugation at 
30000 x g for 20 min, the supernatant was ad- 
sorbed onto a DEAE cellulose column: This 
chromatography and the following hydroxyapatite 
chromatography were carried out as described by 
Maitre et al, [16]. The GABA-T obtained from this 
last step has a specific activity of 0.31 pmollmin 
per mg and was concentrated about IO-fold with 
an Amicon ultrafiltration system. 
2.3. pH optima for the coupled GHB 
dehydrogenase and GABA-T reaction 
300 mM phosphate buffer (pH 5.0-9.5) was 
used. All the substrates, including [3H]GHB 
(700 mCi/mmol) described for the measurement 
of the coupled reaction were added (final GHB 
concentration 30 pM). GABA formation was 
measured as described above. 
2.4. Apparent Km for GHB when GABA-T is 
present in the medium 
When GABA-T was present in the incubation 
medium (10.3 units/5OOpl) the apparent K,,, for 
GHB was determined using r3H]GHB and isolating 
the [3H]GABA formed a~ described above. The in- 
cubation medium contained all the substrates in- 
dicated and GHB (O-60gM). 
The product formed from t3HfGHB after the 
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conjugation of GHB dehydrogenase and GABA-T 
action was identified by dansylation according to 
Zanetta et al. f17]. After separation on Dowex 
50 W X 8, two-Dimensions thin-layer chromatog- 
raphy of the dansylated product was performed 
using pure dansylated amino acids as standards. 
Identification of radioactive spots on the chro- 
matogram was carried out with a Berthold linear 
@counter. 
2.5. Substrate specificities 
Various structural analogues of GHB (1 mM, 
final concentration) were substituted for GHB in 
the standard reaction medium at pH 8.0 and the 
relative initial reaction velocities were compared 
(incubation time 30 min at 37°C). Dehydrogenase 
activity was measured by monitoring NADPH 
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Fig. 1. Determination of optimum pH for the production 
of GABA from [‘H}GHB in the presence of GHB 
dehydrogenase and purified GABA-T. Each point 
represents he mean of 2 experiments. 
fluorescence. For the best substrate, K, values 
were determined. 
3. RESULTS 
3.1, pH optimum 
The pH optimum for GHB dehydrogenase is 
about 9.0 [9]. However, for the coupIed reaction 
(GHB dehydrogenase plus GABA-T), the op- 
timum pH gives a sharp peak at 8.0. At a pH 9.0, 
GABA formation was strongly reduced (fig.1). 
3.2. Apparent Km for transformation f GHB into 
GABA in the presence of GHB dehydroge- 
nase and GABA-T 
In the presence of 2 mM glucuronate, 0.5 mM 
glutamate, 50 ,uM NADP and 0.5 mM pyridoxal 
phosphate, 30 pM [3H]GHB (280 CVmmol), at 
pH 8.0, is transformed into GABA. This reaction 
is linear for 5 min at 37°C (fig.2) when GHB 
dehydrogenase (final concentration 8 units/5~ ,& 
phosphate buffer) and GABA-T (final concentra- 
tion 10.3 units1500 /tl phosphate buffer) are used. 
GHB dehydrogenase or GABA-T incubated alone 
with the same substrates does not produce 
0 5 IO 20 
Fig.2. Time course of [3H]GABA formation from 
[‘H]GHB in the presence of GHB dehydrogenase and 
purified GABA-T. Conditions are indicated in the text. 
Each point represents he mean of 2 dete~~nations. 
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Fig.3. Apparent K, value for GHB in the coupled enzyme reaction. Incubation conditions are given in the text. 
Ordinate: initial rate of [3H]GABA formation. Each point represents he mean of 2 determinations. 
t3H]GABA. With GHB concentrations of 
2-60 FM, and an incubation time of 5 min, an ap- 
parent Km value for the coupled enzyme reaction 
was calculated to be 175 + 75 PM (fig.3). This 
value is about 1%fold lower than the K, value for 
GHB in the presence of GHB dehydrogenase alone 
[9]. The K,,, value determined for the coupled en- 
zyme reaction is in good agreement with the K,,, 
found for the multienzymatic system that 
transforms GHB into GABA in brain tissue slices 
181. For GHB dehydrogenase alone, the Ki for SSA 
(14 c 2 FM) was measured at pH 8.0 with SSA 
concentrations of 2-200 FM. The Ki for NADPH 
was 21 rt 5 GM (not shown). Thus, the presence of 
glucuronate decreases the accumulation of 
NADPH and favors GHB dehydrogenation. 
3.3. Substrate specificity 
Table 1 shows the activities, as substrates of 
GHB dehydrogenase, of a series of compounds 
structurally related to GHB. In particular, cy, ,& or 
y substituted GHB analogues (compounds l-17), 
grassy-hydroxycrotonic acid (@am-HCA), which 
may be considered as extended or semi-extended 
GHB analogues, and y-substituted derivatives 
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(compounds 24-36) were tested, and their activities 
were compared to that of GHB. GHB is probably 
recognized by the enzymatic system in an extended 
or semi-extended conformation, as is shown by the 
high activitv of tram-HCA. On the other hand, 
introduction of substituents generally led to a 
decrease, or complete loss of activity; only slight 
modifications (introduction of a methyl group) are 
tolerated in the LY or ,& position (compounds 
1,3,15,24). 
4. DISCUSSION 
Interest in studying GHB dehydrogenase is 
stimulated by the fact that GHB possesses everal 
interesting neuroactive properties [ 181. In many 
respects, it can be considered as a neurotransmitter 
in brain [l]. Thus, the identification of the 
catabolic route for GHB in brain appears to be of 
importance. 
We have recentIy demonstrated that when GHB 
(in micromolar concentrations) is incubated under 
physiologic~ conditions with rat brain slices, it is 
transformed rapidly into f3H]GABA IS]. This 
catabolism occurs via GABA-T activity since it is 
Table 1 
Substrate specificities 
Substrate Relative K,,, 
activities (mM) 
GHB 100 lo* 3 
1 a-Methyl GHB 73 
2 a-Phenyl GHB 33 
3 &Methyl GHB 167 2.5 + 2 
4 &Ethyl GHB 100 
5 ,&n-Propyl GHB nd 
6 &Isopropyl GHB nd 
7 @Benzyl GHB 27 
8 &Phenyl GHB 7 
9 y-Methyl GHB nd 
10 y-Phenyl GHB nd 
11 y-@-Chloro)phenyl GHB 13 
12 y-(p-Methoxy)phenyl GHB 11 
13 y-(p-Methyl)phenyl GHB 22 
14 y-@-Fluoro)phenyl GHB 26 
15 cu&Dimethyl GHB 613 0.7 f 0.1 
16 Cyclohexanol-2-acetic acid nd 
17 Hydroxymethyl-2-benzoate nd 
18 a-Hydroxybutyrate 17 
19 &Hydroxybutyrate 13 
20 S-Hydroxyvalerate 20 
21 ,&Hydroxypropane sulfonate 33 
22 y-Hydroxybutane sulfonate 20 
23 trans-HCA 140 Sk2 
24 @Methyl tram-HCA 96 
25 &Phenyl trans-HCA 10 
26 y-Methyl tram-HCA 40 
27 y-Cyclohexyl trans-HCA 13 
28 yPheny1 tram-HCA nd 
29 y-@-Nitro)phenyl tram HCA nd 
30 y-(p-Fluoro)phenyl truns-HCA 20 
3 1 y-@-Chloro)phenyl truns-HCA 27 
32 y-@-Methyl)phenyl tram-HCA 24 
33 y-(p-Trifluoromethyl)phenyl 
truns-HCA 26 
34 y-(o-Chloro)phenyl tram-HCA nd 
35 P-Methyl-y-phenyl trans-HCA nd 
36 Cyclohexanol-2-yliden acetic 
acid 60 
nd: not detected under our assay conditions. Each point 
represents the mean of 3 determinations. Km values (for 
GHB dehydrogenase alone - see section 2) were 
determined for the best substrates 
strongly reduced by GABA-T inhibitors. 
Moreover, transformation of glutamate into 
2-ketoglutarate paralleled the synthesis of 
[3H]GABA [8]. It is therefore of interest to show 
that in vitro, the kinetic characteristics of pure 
GHB dehydrogenase coupled to purified GABA-T 
are consistent with the rapid transformation of 
micromolar amounts of GHB present in vivo in rat 
brain [ 191. The enzyme named in the present work 
GHB dehydrogenase appears to be identical to the 
high Km ALRi which has been implicated in D- 
glucuronate and myo-inositol metabolism [lo]. 
The reduction of D-glucuronate can also be cou- 
pled with y-hydroxybutyrate oxidation. We have 
demonstrated that in the presence of glucuronate, 
glutamate, NADP and pyridoxal phosphate, the 
apparent K,,, of GHB for the coupled enzyme reac- 
tion (K,,, = 175 ,uM) is very much closer to the value 
required to metabolize endogenous brain GHB. 
Moreover, in this case, the optimum pH of the 
polyenzymatic reaction (pH 8.0) is more consistent 
with the physiological conditions than the op- 
timum pH of GHB dehydrogenase acting alone 
(pH 9.0). In vitro, in the conditions described, 
GHB at concentrations close to those existing in 
vivo [19] is rapidly converted to GABA despite the 
relatively high K,,, found for the coupled reaction 
in vitro. It seems likely that in vivo the subcellular 
concentrations of GHB are higher than those 
found in whole brain tissue [19]. This synthesis of 
GABA has been confirmed by analysis after dan- 
sylation of the tritiated compound produced by the 
polyenzymatic reaction. This transformation of 
GHB into GABA in vitro, confirmed by ex- 
periments on brain slices [8] is in accordance with 
most previous results (review [8]) although Mohler 
et al. [20] working with [l-14C]GHB administered 
in vivo did not observe the formation of 
[14C]GABA. 
Snead et al. [21] have reported that acute ad- 
ministration of ethosuximide and sodium 
valproate significantly increase the GHB level in 
brain. In view of the demonstrated inhibition of 
these compounds on GHB dehydrogenase, the 
mechanism of this increase in GHB can be ex- 
plained by an inhibition of its degradation. 
Therefore, it seems likely that inhibition of the 
degradation of GHB and an increase of this 
substance in brain might have anticonvulsant 
properties. This result is paradoxical, considering 
that injection of GHB to animals produces a 
modification in the electroencephalographic 
pattern (EEG) which resembles that of petit mal 
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epilepsy [21]. This modification in the EEG profile 
is antagonized by ethosuximide, trimethadione and 
sodium valproate [21]. To explain this apparent 
paradoxical phenomenon, we postulate that inhibi- 
tion of GHB dehydrogenase l ads to a decrease in 
GABA formation from GHB. This GABA pool 
might be involved in the negative feedback regula- 
tion of a GABAergic synapse or of a GHBergic 
synapse. 
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